124 related articles for article (PubMed ID: 36718624)
1. A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
Gao B; Voskoboynik M; Cooper A; Wilkinson K; Hoon S; Hsieh CY; Cai S; Tian YE; Bao J; Ma N; Wang C; Zhang M; Li B; Guo M; Zhou R; Wang X; Xu C; de Souza P
Cancer; 2023 Apr; 129(7):1041-1050. PubMed ID: 36718624
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Cao J; Guo H; Ji D; Shen W; Zhang S; Hsieh CY; Xiong Cai S; Edward Tian Y; Xu C; Zhang P; Xu B
Oncologist; 2023 Dec; 28(12):e1259-e1267. PubMed ID: 37338150
[TBL] [Abstract][Full Text] [Related]
3. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Naito Y; Kuboki Y; Ikeda M; Harano K; Matsubara N; Toyoizumi S; Mori Y; Hori N; Nagasawa T; Kogawa T
Invest New Drugs; 2021 Dec; 39(6):1568-1576. PubMed ID: 34160752
[TBL] [Abstract][Full Text] [Related]
5. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
7. Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Wu X; Liu J; Wang J; Wang L; Lin Z; Wang X; Zhu J; Kong B; Fei J; Tang Y; Xia B; Liang Z; Wang K; Huang Y; Zheng H; Lin A; Jiang K; Wang W; Wang X; Lou G; Pan H; Yao S; Li G; Hao M; Cai Y; Chen X; Yang Z; Chen Y; Wen H; Qu P; Xu C; Hsieh CY;
Nat Med; 2024 Jun; 30(6):1612-1621. PubMed ID: 38750351
[TBL] [Abstract][Full Text] [Related]
8. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
9. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Awada A; Campone M; Varga A; Aftimos P; Frenel JS; Bahleda R; Gombos A; Bourbouloux E; Soria JC
Anticancer Drugs; 2016 Apr; 27(4):342-8. PubMed ID: 26796987
[TBL] [Abstract][Full Text] [Related]
10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
11. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
Nishikawa T; Matsumoto K; Tamura K; Yoshida H; Imai Y; Miyasaka A; Onoe T; Yamaguchi S; Shimizu C; Yonemori K; Shimoi T; Yunokawa M; Xiong H; Nuthalapati S; Hashiba H; Kiriyama T; Leahy T; Komarnitsky P; Fujiwara K
Cancer Sci; 2017 Sep; 108(9):1834-1842. PubMed ID: 28665051
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Yonemori K; Tamura K; Kodaira M; Fujikawa K; Sagawa T; Esaki T; Shirakawa T; Hirai F; Yokoi Y; Kawata T; Hatano B; Takahashi Y
Cancer Chemother Pharmacol; 2016 Sep; 78(3):525-31. PubMed ID: 27422301
[TBL] [Abstract][Full Text] [Related]
16. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study.
Hu X; Hsieh CY; Zhang Y; Liu W; Xu S; Cai SX; Liu L; Zhang M; Shi H; Zhang H; Liu P; Li X; Xu P
Br J Clin Pharmacol; 2023 Jun; 89(6):1767-1779. PubMed ID: 36458825
[TBL] [Abstract][Full Text] [Related]
17. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
18. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.
Takagi M; Ogawa C; Iehara T; Aoki-Nogami Y; Ishibashi E; Imai M; Kimura T; Nagata M; Yasuhara M; Masutani M; Yoshimura K; Tomizawa D; Ogawa A; Yonemori K; Morishita A; Miyamoto S; Takita J; Kihara T; Nobori K; Hasebe K; Miya F; Ikeda S; Shioda Y; Matsumoto K; Fujimura J; Mizutani S; Morio T; Hosoi H; Koike R
Cancer; 2022 Aug; 128(15):2949-2957. PubMed ID: 35593736
[TBL] [Abstract][Full Text] [Related]
19. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
Yonemori K; Shimizu T; Kondo S; Iwasa S; Koyama T; Kitano S; Sato J; Shimomura A; Shibaki R; Suri A; Kase Y; Sumino S; Tamura K; Yamamoto N
Jpn J Clin Oncol; 2021 Apr; 51(5):693-699. PubMed ID: 33621324
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
